Skip to main content

Articles By Janet Pope, MD, MPH, FRCPC

question-mark-1872634_640.jpg

ICYMI: JAKi in inflammatory myositis?

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

ICYMI: Are Emulation Trials a Fantasy?

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
question-mark-1872634_640.jpg

JAKi in inflammatory myositis?

Abstract 1731 is a small RCT of baricitinib in inflammatory myositis comparing early start baricitinib to later start.

Read Article
question mark

Are Emulation Trials a Fantasy?

Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?

Read Article
JAK Janus

New indications for JAK inhibitors

There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.

Read Article
older woman with clasped hands

ICYMI: Who gives a ‘JAK’ why and how they work, as long as they do!

Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

Read Article
puzzle.RA_.jpg

Here’s what will change my practice in Rheumatoid Arthritis

Here's what I learned at ACR23 that will change the way I practice in rheumatoid arthritis. 

Read Article
Choices

JAKi and TYK2i: What to use and when?

You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.

Read Article
older woman with clasped hands

Who gives a ‘JAK’ why and how they work, as long as they do!

Several abstracts have studied the mechanism of action of JAK inhibitors (JAKi) in various diseases. JAKi alter many other mediators affected by the JAK STAT pathway. For instance, T cell signature in blood that is proliferative was associated with a response in RA.

Read Article
×